GlaxoSmithKline Forms US$650 M Epigenetics Alliance with Epizyme |
Abstract
|
Heather Cartwright |
|
Pfizer Licenses Seattle Genetics’ Antibody-Drug Conjugate Technology |
Abstract
|
Heather Cartwright |
|
Merck Serono and Domain Therapeutics Partner to Develop Positive Allosteric Modulators for Parkinson’s Disease |
Abstract
|
Heather Cartwright |
|
Theraclone Sciences Signs its First Major Antibody Deal with Pfizer |
Abstract
|
Heather Cartwright |
|
Oncolys Out-Licenses Phase II HIV Drug to Bristol-Myers Squibb |
Abstract
|
Heather Cartwright |
|
Xoma Partners with Servier to Develop and Commercialise its Lead Anti-Inflammatory Drug |
Abstract
|
Heather Cartwright |
|
Reckitt Benckiser to Acquire India’s Paras Pharmaceuticals for US$725 M |
Abstract
|
Heather Cartwright |
|
Gilead Strengthens its Early-Stage Pipeline by Acquiring Arresto Biosciences |
Abstract
|
Heather Cartwright |
|
Biogen Idec Expands its Neurology Pipeline by Acquiring Three Programmes from Neurimmune |
Abstract
|
Heather Cartwright |
|
Biotie Therapies Expands CNS Pipeline with Acquisition of Synosia Therapeutics |
Abstract
|
Heather Cartwright |
|
Sanofi-aventis Forms Covalent Drug Discovery Partnership with Avila Therapeutics in Oncology |
Abstract
|
Heather Cartwright |
|